APIM Therapeutics
Targeting stress responses in cancer and inflammation via a first-in-class therapeutic approach.
Norway
7 employees
Series Unknown
Total: $25.00M
Biotechnology, Finance +1
General Information
Get notified when APIM Therapeutics moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Track APIM Therapeutics
Get real-time alerts for funding, hiring, news, and 40+ signal types.
See how it worksDiscover More
Norway Market
Biotechnology
About APIM Therapeutics
Taxonomy: biotech company, therapeutic approach, oncology, inflammation, novel treatments, venture capital financed, Norwegian, ATX-101, phase I study, solid tumors, peptide drug candidate, cellular stress defense mechanisms
Funding Rounds & Investors (3)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Venture Round | •••••• | 1 |
|
08 Dec 2017 |
| Venture Round | •••••• | 3 |
|
17 Oct 2012 |
| Venture Round | •••••• | 2 |
|
10 Nov 2011 |
APIM Therapeutics Alternatives & Competitors
Advancing Next-Generation Antibody Drug Conjugates Designed with Novel ImmunoOncology Payloads
Harnessing heavy metals to improve human health
Targeting the pathology—not the pathogen
FAQ About APIM Therapeutics
Don't just browse. Track.
Signal Tracker monitors APIM Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.